ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$87.11

Market cap

$12.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.25

Enterprise value

$13.63B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 30

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies ...

Highlights
The gross profit is up by 17% YoY and by 8% QoQ
The company's revenue rose by 17% YoY and by 8% QoQ
The quick ratio has increased by 21% YoY but it has decreased by 7% from the previous quarter
The net income has dropped by 116% year-on-year and by 6% since the previous quarter
Arrowhead Pharmaceuticals's debt has surged by 93% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-0.41%
1 week
0.54%
1 month
16.89%
1 year
319.81%
YTD
31.21%
QTD
6.87%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$669.5M
Gross profit
$669.5M
Operating income
-$226.44M
Net income
-$319.95M
Gross margin
100%
Net margin
-47.8%
The net income has dropped by 116% year-on-year and by 6% since the previous quarter
The operating income has dropped by 110% year-on-year and by 2% since the previous quarter
Arrowhead Pharmaceuticals's net margin has shrunk by 85% YoY
The operating margin has dropped by 80% year-on-year but it has increased by 5% since the previous quarter

Price vs fundamentals

How does ARWR's price correlate with its fundamentals

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
ARWR P/E details
P/E
N/A
P/B
26.36
P/S
18.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.35
ARWR's EPS has plunged by 81% YoY and by 4.7% from the previous quarter
The price to book (P/B) is 97% higher than the 5-year quarterly average of 13.4 and 62% higher than the last 4 quarters average of 16.3
The equity has contracted by 24% from the previous quarter and by 11% YoY
The price to sales (P/S) is 82% less than the 5-year quarterly average of 106.1 but 64% more than the last 4 quarters average of 11.4
The company's revenue rose by 17% YoY and by 8% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
ARWR's ROS has plunged by 177% YoY
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 136% YoY but it has increased by 7% QoQ
The company's return on assets has shrunk by 50% YoY but it rose by 3.9% QoQ
The company's return on equity fell by 47% YoY and by 9% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 28% higher than its total liabilities
The total liabilities has surged by 91% year-on-year
ARWR's total assets has soared by 53% YoY but it is down by 7% QoQ
Arrowhead Pharmaceuticals's debt is 196% higher than its equity
The debt to equity has soared by 116% YoY and by 32% from the previous quarter
Arrowhead Pharmaceuticals's debt has surged by 93% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.